Top Tweets for #31R

about 3 years ago

$RVV Revive Therapeutics files patent application to treat chemical warfare agents exposure https://t.co/HffvALHLXo $31R $RVVTF #RVV #31R #RVVTF

0

6

2

0

297

over 3 years ago

$RVV Revive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDA https://t.co/PCrsXXvy4S $31R $RVVTF #RVV #31R #RVVTF

0

10

3

0

392

over 3 years ago

$RVV Revive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next steps https://t.co/FK2SPUqYEy $31R $RVVTF #RVV #31R #RVVTF

0

10

2

0

534

over 3 years ago · Los Angeles

$RVVTF Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial https://t.co/iLBHwmyPl1 @Revive_RVV $31R $RVVTF #RVV #31R #RVVTF

0

11

1

0

310

over 3 years ago

$RVVTF Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial https://t.co/iLBHwmyPl1 @Revive_RVV $31R $RVVTF #RVV #31R #RVVTF

0

11

2

0

256

over 3 years ago

$RVV Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial https://t.co/L5wrzvpDbx $31R $RVVTF #RVV #31R #RVVTF

0

12

3

0

310

over 3 years ago · Los Angeles

$RVVTF Revive Therapeutics to review next steps for COVID-19 study https://t.co/EHZ4g32IOh @Revive_RVV $31R $RVVTF #RVV #31R #RVVTF

0

12

4

0

461

over 3 years ago

$RVV Revive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patients https://t.co/XTdZb6GaWi $31R $RVVTF #RVV #31R #RVVTF

0

8

2

0

425

over 3 years ago

$RVVTF Revive Therapeutics advances MDMA transdermal patch development with purchase of MDMA supply from PharmAla Biotech https://t.co/OAKWo2FrwC @Revive_RVV $31R $RVVTF #RVV #31R #RVVTF

0

12

2

0

855

over 3 years ago

$RVV Revive Therapeutics advances MDMA transdermal patch development with purchase of MDMA supply from PharmAla Biotech https://t.co/DRWmdNxIJ9 $31R $RVVTF #RVV #31R #RVVTF

0

13

6

0

600

over 3 years ago

$RVV Revive Therapeutics enrols first patient in psilocybin clinical study for methamphetamine use disorder https://t.co/3iw436CC88 $31R $RVVTF #RVV #31R #RVVTF

0

12

4

0

571

over 3 years ago

$RVV Revive Therapeutics provides update of Phase 3 clinical study for Bucillamine in treatment of COVID-19 https://t.co/OhyGz2iafn $31R $RVVTF #RVV #31R #RVVTF

0

6

1

0

399

over 3 years ago

$RVV Revive Therapeutics reveals positive update on FDA meeting for Bucillamine study in treatment of COVID-19 https://t.co/oixVn81o5C $31R $RVVTF #RVV #31R #RVVTF

0

14

3

0

681

over 3 years ago

$RVV Revive Therapeutics secures supply of MDMA from PharmaAla Biotech for transdermal patch development https://t.co/ndvNiSrZWr $31R $RVVTF #RVV #31R #RVVTF

0

11

2

0

459

over 3 years ago

$RVV Revive Therapeutics enters into research collaboration agreement with PharmaTher to develop MDMA transdermal patch https://t.co/VFV0zeeRR1 $31R $RVVTF #RVV #31R #RVVTF

0

17

2

0

547

over 3 years ago

$RVV Revive Therapeutics submits updated briefing package to FDA for COVID treatment https://t.co/afQ5OdEtWU $31R $RVVTF #RVV #31R #RVVTF

0

10

3

0

516

over 3 years ago

$RVV Revive Therapeutics closes previously announced private placement for gross proceeds of $4,301,409 https://t.co/FN94hCm4B6 $31R $RVVTF #RVV #31R #RVVTF

0

8

0

228

almost 4 years ago

$RVV Revive Therapeutics says arranging private placement of up to $5M of units at a price of 15 cents each https://t.co/zbbHnqiDyn $31R $RVVTF #RVV #31R #RVVTF

0

6

1

0